Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Shanghai Yinnuo Pharmaceutical Technology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China, Brazil and Australia registers with Shanghai Yinnuo Pharmaceutical Technology as lead sponsor. Synced 12 Nov 2026
4Current trials
2Recruiting now
1Drug in these trials
3Trial registers
At a glance

Shanghai Yinnuo Pharmaceutical Technology is the lead sponsor of 4 current clinical trials in our China, Brazil and Australia registers. 2 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Efsubaglutide Alfa. The most-studied condition is Obesity and Overweight.

ClinicalTrials.gov trials by status

  • Recruiting250%
  • Not yet open125%
  • Active, closed125%

Trials by phase

  • Phase 1250%
  • Phase 2/3125%
  • Phase 2125%
01

Clinical trials sponsored by Shanghai Yinnuo Pharmaceutical Technology

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents
NCT07693426 · ClinicalTrials.gov ↗ · Adolescence Obesity
Phase 1 Recruiting 2026-07 China
The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)
NCT07114419 · ClinicalTrials.gov ↗ · Obesity and Overweight
Phase 2 Recruiting 2025-08 Australia
A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil
NCT07518121 · ClinicalTrials.gov ↗ · Diabete Type 2
Phase 1 Not yet open 2026-06 Brazil
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
NCT06921486 · ClinicalTrials.gov ↗ · Obesity and Overweight
Phase 2/3 Active, closed 2025-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shanghai Yinnuo Pharmaceutical Technology trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shanghai Yinnuo Pharmaceutical Technology trials

3 conditions
Obesity and Overweight2Adolescence Obesity1Diabete Type 21
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China21
Clinical trials in Brazil10
Clinical trials in Australia11

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Obesity and Overweight

SponsorTrials
Fundació d'investigació Sanitària de les Illes Balears1
Lallemand Health Solutions1
Paracelsus Medical University1

Sponsors with the most current trials registered for this condition.

06

Questions about Shanghai Yinnuo Pharmaceutical Technology trials

How many clinical trials does Shanghai Yinnuo Pharmaceutical Technology sponsor?

Shanghai Yinnuo Pharmaceutical Technology is the lead sponsor of 4 current trials on ClinicalTrials.gov in our China, Brazil and Australia registers, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.

Are Shanghai Yinnuo Pharmaceutical Technology trials recruiting?

Yes. 2 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Yinnuo Pharmaceutical Technology testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Efsubaglutide Alfa (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.